Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5093862
Max Phase: Preclinical
Molecular Formula: C29H36F2N8O2
Molecular Weight: 566.66
Molecule Type: Unknown
Associated Items:
ID: ALA5093862
Max Phase: Preclinical
Molecular Formula: C29H36F2N8O2
Molecular Weight: 566.66
Molecule Type: Unknown
Associated Items:
Canonical SMILES: Cc1nnc2c(NCCCN3CCC(F)(F)CC3)cc(C(=O)N3[C@@H]4c5ccccc5C[C@H]3C(=O)N[C@@H]4C(C)C)nn12
Standard InChI: InChI=1S/C29H36F2N8O2/c1-17(2)24-25-20-8-5-4-7-19(20)15-23(27(40)33-24)38(25)28(41)22-16-21(26-35-34-18(3)39(26)36-22)32-11-6-12-37-13-9-29(30,31)10-14-37/h4-5,7-8,16-17,23-25,32H,6,9-15H2,1-3H3,(H,33,40)/t23-,24+,25+/m0/s1
Standard InChI Key: MMNMOVIEDRHEDO-ISJGIBHGSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 566.66 | Molecular Weight (Monoisotopic): 566.2929 | AlogP: 3.23 | #Rotatable Bonds: 7 |
Polar Surface Area: 107.76 | Molecular Species: NEUTRAL | HBA: 8 | HBD: 2 |
#RO5 Violations: 1 | HBA (Lipinski): 10 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 12.49 | CX Basic pKa: 8.24 | CX LogP: 2.18 | CX LogD: 1.29 |
Aromatic Rings: 3 | Heavy Atoms: 41 | QED Weighted: 0.42 | Np Likeness Score: -0.85 |
1. Winter-Holt JJ, Bardelle C, Chiarparin E, Dale IL, Davey PRJ, Davies NL, Denz C, Fillery SM, Guérot CM, Han F, Hughes SJ, Kulkarni M, Liu Z, Milbradt A, Moss TA, Niu H, Patel J, Rabow AA, Schimpl M, Shi J, Sun D, Yang D, Guichard S.. (2022) Discovery of a Potent and Selective ATAD2 Bromodomain Inhibitor with Antiproliferative Activity in Breast Cancer Models., 65 (4.0): [PMID:35133824] [10.1021/acs.jmedchem.1c01871] |
Source(1):